Sanofi - Strong presence with established GLP-1 therapies like Soliqua and Lyxumia, focusing on combination approaches for type 2 diabetes
Meanwhile, the spending level in Finland, Denmark, Ireland, France, Luxembourg, Belgium, Sweden, the Netherlands, and Austria is above the average of USD 3,814, thus enhancing the market exposure
Allen RE, Dodson MV, Luiten LS: Regulation of skeletal muscle satellite cell proliferation by bovine pituitary fibroblast growth factor
However, systemic administration of immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) often faces limitations such as poor tumor targeting, difficulty in penetration, and triggering autoimmune side effects, which restrict the full exertion of their efficacy [89]
Available at: No